5-BROMO-7H-PYRROLO[2,3-D]PYRIMIDINE-2-CARBOXYLIC ACID METHYL ESTER, 95.0%, 250mg

(3R,4S,5S,7aR)-3,5,6,7a-Tetramethyl-1-oxo-N,N-diphenyl-1,3,3a,4,5,7a-hexahydroisobenzofuran-4-carboxamide, 97%, 1g

(2E)-1-(4-methoxyphenyl)-3-(3-methylphenyl)prop-2-en-1-one, 95.0%, 10g

4-ethyl-5-[1-(4-fluorophenoxy)ethyl]-4H-1,2,4-triazole-3-thiol, 95.0%, 5g

Gold ICP-Standardlösung, ROTI®Star, 1000 mg/l Au, Dichte (D) 1,01 g/cm³

Tenalisib, 10mg

5-Bromo-3,3-dimethyl-2,3-dihydro-1H-inden-1-ol, 97%, 250mg

(2R)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-3-[[(4-methylphenyl)-diphenylmethyl]amino]propanoic acid, 95%, 2g

3-methyl-1-vinyl-1H-pyrazole-4-carbaldehyde, 95.0%, 50g

3-Bromo-1H-indol-5-amine hydrochloride, 100mg

(S)-1-(4-Bromophenyl)ethanol, 95.0%, 5g

3,4-Difluorotoluene>98.0%(GC)1g

1-(TERT-BUTOXYCARBONYL)-3-FLUOROPYRROLIDINE-3-CARBOXYLIC ACID, 95.0%, 1g